Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities

• Published in: Journal of allergy and clinical immunology Vol. 147; no. 4; pp. 1369 - 1380
• Main Authors: He, Helen, Del Duca, Ester, Diaz, Aisleen, Kim, Hyun Je, Gay-Mimbrera, Jesús, Zhang, Ning, Wu, Jianni, Beaziz, Jessica, Estrada, Yeriel, Krueger, James G., Pavel, Ana B., Ruano, Juan, Guttman-Yassky, Emma
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2021; Elsevier Limited
• Subjects: Age; Arteriosclerosis; Atherosclerosis; Atopic dermatitis; Biopsy; Cardiovascular disease; Cardiovascular diseases; CCL17 protein; CCL20 protein; Cell activation; CXCL10 protein; cytokines; Dendritic cells; Dermatitis; Eczema; Foxp3 protein; Gene expression; Helper cells; Hyperplasia; Hypothesis testing; immune tolerance; Immunohistochemistry; Inflammation; Insulin-like growth factor-binding protein 1; Interleukin 1; Interleukin 10; Interleukin 13; Interleukin 22; limited; Lymphocytes T; mild; OLINK; Patients; Proteomics; Psoriasis; qRT-PCR; severity; Skin; Skin diseases; Skin lesions; Software; systemic inflammation; severity; CXCL; SCORAD; IGA; AD; proteomics; limited; mild; qRT-PCR; Treg; OSM; HR; CCL; systemic inflammation; BSA; immune tolerance; Atopic dermatitis; OLINK; cytokines; DC
• ISSN: 0091-6749; 1097-6825; 1097-6825
• DOI: 10.1016/j.jaci.2020.08.041

Molecular studies in atopic dermatitis (AD) are largely restricted to patients with moderate-to-severe disease. Our aim was to evaluate skin and blood abnormalities in mild, moderate, and severe AD. Skin and blood samples were obtained from 61 patients with AD (20 with mild or limited disease, 17 with moderate disease, and 24 with severe disease) and 20 healthy subjects. Immune and barrier markers were measured in lesional, nonlesional, and healthy skin by quantitative real-time PCR and immunohistochemistry, and in blood by using the OLINK proteomic assay. Cellular markers of epidermal hyperplasia and T-cell/dendritic cell infiltration were increased in AD tissues of all patients in all severity groups versus in those of controls, whereas downstream TH2 cell–, TH22 cell–, TH1 cell–, and TH17 cell–related mediators demonstrated incremental elevations with increasing disease severity, in both lesional and nonlesional skin. Whereas the levels of the TH2 (IL13, CCL17, and CCL26) and TH22 (IL-22) cytokines were significantly elevated in both AD lesional and nonlesional skin of all patients regardless of the severity of their disease, patients with mild or limited AD showed increases in their levels of TH1 cell (IFNG, CXCL9, and CXCL10) and TH17 cell (IL-17A, CCL20, and CXCL1) markers in lesional but not nonlesional skin. Regulatory T-cell–related mediators (IL-10 and FOXP3) were comparably upregulated in all groups, without displaying the severity-based gradient in other immune axes. Unsupervised clustering aligned samples along a severity spectrum, where nonlesional mild or limited AD skin clustered with the samples from healthy controls. Furthermore, whereas the blood profiles of patients with moderate and severe AD showed gradual increases in the levels of TH1 cell–, TH2 cell–, and TH17 cell–related and atherosclerosis and/or cardiovascular risk (CCL7, FGF21, and IGFBP1) proteins, the blood profiles of patients with mild or limited AD lacked significant differences from those of the controls. Mild and limited AD show high levels of TH2/TH22 cell activation that is primarily localized to skin lesions and lacks the systemic inflammation of moderate and severe disease. [Display omitted]